友情提示:以下期刊信息可能会有更新,仅供参考,请在投稿前自行登录期刊官网仔细核实。
期刊名
Frontiers in Bioengineering and Biotechnology
FRONT BIOENG BIOTECH
ISSN / eISSN
2296-4185 / 2296-4185
目标和范围
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
研究方向
综合性期刊
CiteScore
6.70
查看趋势图
CiteScore 学科排名
类别 | 分区 | 排名 |
---|---|---|
Medicine - Histology | Q1 | #11/57 |
Medicine - Biotechnology | Q2 | #84/299 |
Medicine - Biomedical Engineering | Q2 | #85/277 |
Medicine - Bioengineering | Q2 | #55/153 |
Web of Science 核心合集
Science Citation Index Expanded (SCIE) | Social Sciences Citation Index (SSCI) |
---|---|
Indexed | - |
类别 (Journal Citation Reports 2023) | 分区 |
---|---|
MULTIDISCIPLINARY SCIENCES - SCIE | Q1 |
出版国家或地区
Switzerland
出版商
Frontiers Media S.A.
年文章数
2380
Open Access
YES
通讯方式
AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, SWITZERLAND, CH-1015
认证评论
Received date: 29 Nov 2022
Editorial assignment start date: 29 Nov 2022
Independent review start date: 07 Dec 2022
Interactive review activated date: 06 Jan 2023
Review finalized date: 08 Feb 2023
Final validation date: 09 Feb 2023
Frontiers currently has three risk journals, but compared to other journals, FIBB doesn't need to worry about risks for now. Overall, it is still acceptable as it is a Q2 journal in the Chinese Academy of Sciences and has already achieved Q1 in JCR. It is recommended to submit the manuscript avoiding Christmas and Chinese New Year to speed up the process. Also, the fee of $3250 is a bit expensive.
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started